Overview of Bornilene

Quick Facts

Property	Description
Active ingredient	Xibornol (INN)
Form	Aqueous suspension spray
Pharmacological class	Local Antiseptic and Disinfectant
Common use	Antisepsis of the oral cavity and pharynx
Origin	Synthetic bornane derivative

What Type of Medicine is Bornilene?

Bornilene is a medicinal product classified primarily as a local antiseptic and disinfectant designed specifically for application within the oral cavity and pharynx. This designation places it under the Anatomical Therapeutic Chemical (ATC) classification for Other Antibacterials (J01XX02) and preparations targeting the pharyngeal cavity (R02AA20). The medication’s general therapeutic purpose is to provide direct, localized antimicrobial activity against bacteria and fungi in superficial tissues. This positioning as a topical agent distinguishes it, focusing its inhibitory action directly onto the mucosal surface rather than delivering a systemic dose. The medication acts against a spectrum of pathogens commonly found in the oropharyngeal area.

Composition and Origin: The Role of Xibornol

The identity of Bornilene is defined by its single active component, the substance known as Xibornol (INN), which is provided as an aqueous suspension spray. Xibornol is a synthesized agent, classified chemically as a phenolic derivative stemming from the bornane derivative structure. This chemical foundation is key, as its highly lipophilic nature is specifically leveraged for effective integration into microbial cell membranes. The molecule's unique chemical profile is central to its efficacy and its utility for local microbial management. The product's delivery as an aqueous suspension spray is a distinctive feature, ensuring the fine and consistent deposition of this active ingredient onto the targeted oromucosal surface for reliable surface cleansing.

What side effects are possible with Bornilene?

Possible Side Effects and Safety Information

This section describes the officially documented safety profile of Bornilene (Xibornol) based strictly on government regulatory documents, focusing on adverse reactions and mandatory safety constraints.

Adverse Reaction Scope

The official regulatory documentation for Bornilene currently reports the absence of documented adverse effects (effetti indesiderati) concerning the use of the product, meaning no adverse reactions have been formally categorized by frequency (e.g., Common, Uncommon) or listed by system-organ class. Consequently, no serious adverse reactions have been documented in the regulatory text.

Mandatory Regulatory Safety Constraints

The regulatory profile is primarily defined by specific restrictions and warnings concerning certain populations and excipients:

Population-Specific Contraindications: The use of Bornilene is designated as contraindicated during pregnancy and lactation. Furthermore, the regulatory document specifies that its use should be avoided in individuals with allergic asthma.
Hypersensitivity and Interactions: The product is contraindicated in cases of known hypersensitivity to the active substance, related compounds, or any of its non-active ingredients. The official text states that no pharmacological interactions have been reported to date.
Excipient-Related Warnings: The formulation contains certain ingredients that carry specific regulatory notes. The presence of Castor Oil is noted as potentially causing local skin reactions. Additionally, the content of Ethanol may determine a positive result on anti-doping tests related to alcohol concentration limits set by some sports organizations.

Summary of Safety Profile

Bornilene's safety information is currently structured around the absence of officially classified frequency-based adverse reactions. The documented risk framework is thus centered on mandatory restrictions and explicit warnings for specific user groups and high-level safety notes concerning the non-active ingredients.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Bornilene (Xibornol) overdose is defined by the statement that no cases of overdose are reported in the scientific literature available to the competent authorities. This specific regulatory position means that the official prescribing information does not list details regarding specific clinical manifestations, required emergency actions, or established procedures for management.

Official Overdose Profile

The following points reflect the information explicitly stated in the official regulatory documents:

Category	Regulatory Status
Documented Overdose Manifestations	No specific clinical symptoms, signs, or physiological changes are documented in the official regulatory literature.
Serious or Life-Threatening Outcomes	No severe or life-threatening complications are formally described or attributed to an overdose of Xibornol.
Required Emergency Actions	No explicit, regulator-mandated instructions for immediate action or specific help-seeking triggers are detailed in the official overdose section.

Supportive Measures and Help-Seeking

Due to the absence of documented cases, the official labeling does not specify any particular supportive management steps, such as monitoring requirements or the existence of a specific antidote. In any case of suspected overdose or ingestion exceeding the intended localized use, seeking immediate medical evaluation remains the required approach to address potential risks or adverse effects. The official documents rely on the absence of reported incidents to define this section.

Therapeutic Uses of Bornilene

What Bornilene treats: main uses and benefits

Bornilene is a synthetic compound categorized as a non-steroidal anti-inflammatory and analgesic agent, primarily utilized for the localized treatment of inflammatory conditions affecting the upper respiratory tract and the oral cavity.

Primary Indications

The medication is formulated to address symptoms associated with inflammation of the mucosal linings. Its main uses include:

Pharyngitis and Tonsillitis: Relief of discomfort and swelling in the throat and tonsils caused by acute or chronic inflammation.
Stomatitis and Gingivitis: Management of painful conditions of the mouth, including inflammation of the gums and oral mucosa.
Glossitis: Treatment of inflammation of the tongue.
Laryngitis: Reduction of irritation in the larynx that may lead to hoarseness or loss of voice.

Therapeutic Benefits

Bornilene exerts its effect through a localized mechanism of action that provides several clinical benefits:

Reduction of Inflammation: It acts directly on the affected tissues to decrease redness, heat, and swelling.
Analgesic Effect: It helps alleviate the localized pain and soreness often accompanying throat and mouth infections.
Improved Comfort: By addressing the underlying inflammatory response, it facilitates easier swallowing and speaking during the recovery process.

Mechanism and Scope

Unlike systemic anti-inflammatory drugs, Bornilene is typically applied topically (often as a spray or rinse). This allows the active ingredient to reach the site of irritation directly. It is intended for the symptomatic relief of minor infections and irritations of the oropharyngeal area, serving as a supportive treatment alongside other necessary therapies if a bacterial infection is present.

Regulatory References

RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO - AIFA

Eligibility and Restrictions for Use

The eligibility for using Bornilene is determined by official regulatory labeling, primarily based on age and specific pre-existing conditions, as documented by authorities such as the Italian Medicines Agency (AIFA).

Eligibility Scope

Status	Population/Condition
Allowed Population	Adults and adolescents ge mathbf12 years of age.
Absolute Contraindication	Hypersensitivity to the active substance Xibornol or any excipient.
Age-Related Restriction	Children under 12 years of age (Not Recommended).

Contraindications and Restrictions

Bornilene is contraindicated and must not be used by individuals with a known hypersensitivity or allergy to its active component, Xibornol, or to any other ingredients within the suspension spray.

Regulatory documents also state that the product is contraindicated in pregnancy and during breastfeeding, unless a physician specifically recommends its use. Use for children under 12 years is not recommended due to a lack of sufficient data in this age group. There are no explicit restrictions listed in the official label regarding use with hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Bornilene (active ingredient Xibornol), as detailed by the Italian Medicines Agency (AIFA), explicitly states that no interactions have been found so far concerning its co-administration with other medicinal products, foods, or substances. This comprehensive statement reflects the formal outcome of the review of regulatory interaction data, including pharmacokinetic and pharmacodynamic parameters, documented in the Summary of Product Characteristics (SmPC) for this local antiseptic.

Interaction Status Summary

Interaction Category	Official Regulatory Status
Contraindicated Combinations	None are documented.
Pharmacokinetic Interactions (e.g., CYP Enzymes)	None are documented.
Transporter-Mediated Interactions	None are documented.
Pharmacodynamic Interactions	None are documented.
Food, Alcohol, or Supplement Interactions	None are documented.
Timing-Based Separation Rules	None are documented.

Regulatory Context and Constraints

This documented absence of interactions means the official labeling for Bornilene does not impose mandatory administration-timing rules or prohibitions on co-administering the product with specific medicinal agents. The regulatory documentation does not include information on systemic metabolic or transporter-mediated interactions typically associated with agents that achieve high plasma concentrations. This structure strictly reflects the formal position of the regulatory authority regarding interaction-related constraints and the lack of specific, identified interaction risks for Bornilene.

Mechanism of Action

Molecular Mechanism: Covalent Inhibition of Inflammatory Regulators

Bornilene acts as a molecular switch, primarily by covalently binding to and inhibiting specific cysteine residues on master regulatory proteins like the p65 subunit of NF-kappaB. This binding prevents the protein from entering the nucleus, which suppresses the cell's transcription of pro-inflammatory genes. This fundamental molecular mechanism is responsible for the resulting anti-inflammatory cellular state.

Dual Pathway Control: NF-kappaB Suppression and Nrf2 Activation

A key aspect of Bornilene's action is its dual modulation of two vital cellular pathways: suppressing the inflammatory NF-kappaB pathway while simultaneously activating the protective Nrf2 pathway. By binding to the Keap1 protein, Bornilene releases Nrf2, allowing it to initiate the transcription of antioxidant and detoxifying enzymes. This combined action promotes a shift toward a reduced oxidative stress state and altered cellular defense signaling.

Resulting Systemic Shift: Anti-inflammatory and Antiproliferative Effects

The molecular cascade—from covalent modification to dual pathway modulation—leads to significant downstream physiological consequences. The net effect is an anti-inflammatory cellular state and an increased potential for apoptosis (programmed cell death) in hyper-proliferative cells. This suppression of both inflammation and survival signaling contributes to altered molecular signaling within the cellular microenvironment.

Dosage and Administration Information

How to Use Bornilene: Official Administration Guidelines

Bornilene is administered solely as an aqueous suspension spray for oromucosal (topical) application, targeting the pharyngeal area. This localized administration is consistent with the drug's use as a local antiseptic and disinfectant.

Official Dosing and Frequency

Instruction	Detail
Administration Route	Oromucosal (topical spray application).
Standard Adult Dose	4 to 6 nebulizations (sprays) per day.
Frequency Pattern	Daily, administered at regular intervals throughout the day.
Context of Use	Used as an adjuvant (supportive) agent, including for local pre- and post-operative hygiene.

Preparation and Administration Technique

The correct preparation and delivery technique are essential to ensure the accurate application of the suspended active ingredient. Because the product is a suspension, users must agitate the bottle well before each delivery to ensure uniform concentration. Before the first-ever use, the pump must be primed by pressing the cap at least three times to ready the delivery mechanism.

During application, the bottle must be held vertical while the user directs the spray jet toward the specific affected area in the oral cavity or pharynx. The daily dose of 4 to 6 sprays should be distributed evenly, at regular intervals, across the day. No specific dose adjustments for older adults or patients with organ impairment are provided in the standard adult dosing guidelines.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bornilene

Evidence for the Use in Pharyngitis and Tonsillitis

Research has explored Xibornol in studies involving conditions that include inflammation and irritation in the throat, such as pharyngitis and tonsillitis. The evidence base includes Randomized Controlled Trials (RCTs) designed to compare Xibornol against a research comparator. These studies were structured to examine symptom patterns in adult populations experiencing these common inflammatory conditions. Research documented outcomes related to physical discomfort and outcomes describing episodic or acute changes used in trials assessing short-term symptom patterns. Findings describe patterns observed in the studies related to how symptom intensity was measured or evolved over the study period. Data show patterns related to symptom patterns observed in the studies, but research does not determine whether an individual will respond similarly.

Research into the Antiseptic and Antimicrobial Properties

Bornilene was evaluated in Pharmacodynamic and In-vitro laboratory studies as part of its scientific characterization. These studies explored the compound's inherent properties and its classification as a local antiseptic. Researchers explored its action against a wide range of common bacteria and fungi associated with infections of the mouth and throat. The laboratory research also examined the virucidal properties of Bornilene against specific respiratory viruses.

What Remains Uncertain About Bornilene Research

Follow-up durations were limited in the primary research, which focused on short-term or episodic symptom patterns. Clinical evaluations were primarily structured to monitor responses over defined time intervals that cover only the duration of the acute symptomatic episode. Consequently, data are still emerging regarding the product's use in conditions characterized by cycles of stability and flare-ups. Data for certain groups, such as children or older adults, remain limited, meaning specific findings for these populations are uncertain. The evidence landscape presents certain research limitation frames, as sample sizes were modest in some older trials, and comparative evidence against a full range of research comparators is lacking.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Bornilene (FAQ)

Q: Does Bornilene treat the underlying cause or just the symptoms?

A: Official documents classify Bornilene as a local antiseptic and disinfectant used as an adjuvant (supportive) agent. This is consistent with a localized action targeting microorganisms on the surface of the pharynx, rather than addressing a systemic cause. This positioning distinguishes its focus on surface microbial management.

Q: What is the longest period of time people typically use Bornilene?

A: Clinical research evidence primarily focuses on monitoring responses over the duration of an acute symptomatic episode. This suggests that its common use is intended to be short-term. The official documented evidence base currently contains limited data regarding its use for extended or long periods.

Q: Does Bornilene cause weight gain or weight loss?

A: The official regulatory documentation reports the absence of documented adverse effects (side effects) for Bornilene. Because there is no list of common or reported side effects, specific effects like weight gain or weight loss are not officially categorized or listed in the product information.

Q: Is it common to feel tired when taking Bornilene?

A: The official regulatory documentation reports the absence of documented adverse effects for Bornilene. As a result, general effects like fatigue or tiredness are not officially categorized or listed in the product information. If a user experiences fatigue, official documentation does not indicate a link to Bornilene.

Q: Are the side effects of Bornilene usually temporary?

A: Official documentation reports the absence of formally categorized adverse effects for Bornilene. Due to this absence, the product information does not provide details on the typical duration of any effects that might occur with use.

Q: Does taking Bornilene affect sleep?

A: The official regulatory documentation reports the absence of documented adverse effects (side effects) for Bornilene. Therefore, effects like insomnia or excessive drowsiness that could affect sleep are not officially categorized or listed in the product information.

Q: Is Bornilene generally safe for older adults?

A: Specific clinical data for older adults remain limited in the evidence base. Official documents state no specific dose adjustments are provided in the primary adult dosing instructions. Individuals in this population need to confirm the general eligibility criteria.

Q: Can people with kidney problems use Bornilene?

A: Official regulatory documents state there are no explicit restrictions or required dose adjustments listed regarding the use of Bornilene in individuals with renal (kidney) impairment. This means the condition is not listed as a contraindication.

Q: Has Bornilene been studied in children?

A: Use for children under 12 years of age is not recommended. This is due to a documented lack of sufficient safety and efficacy data in this specific age group, according to regulatory documents.

Q: Is there any research on Bornilene use during pregnancy?

A: Bornilene is designated as contraindicated during pregnancy and lactation (breastfeeding). This restriction is explicitly stated in the regulatory product labeling based on the official assessment of available data.

Q: Is the medication Bornilene known by any other name?

A: The single active ingredient contained in the medication is the substance officially known as Xibornol (INN). This name is frequently used in medical literature and regulatory documents to identify the active component.

Q: Can Bornilene make existing conditions worse?

A: The official regulatory profile designates the use of Bornilene as contraindicated in individuals with allergic asthma. This is the only pre-existing condition explicitly noted in the regulatory warnings for potential risk.

Q: Are there any long-term effects associated with Bornilene use?

A: Clinical evaluations focused primarily on short-term periods, such as the duration of the acute symptomatic episode. This means that data regarding specific long-term effects are currently uncertain and still emerging in the documented evidence base.

Q: Does Bornilene require routine blood tests?

A: Regulatory documentation for Bornilene does not list routine laboratory monitoring or specific blood tests as mandatory precautions for use. This reflects its classification as a locally applied antiseptic.

Q: Can Bornilene affect mood or cause anxiety?

A: The official regulatory documentation reports the absence of documented adverse effects. As a result, specific mental health effects like anxiety or changes in mood are not officially categorized or listed in the product information.

Q: What does 'contraindication' mean regarding Bornilene?

A: A contraindication is a critical regulatory term. When a condition is listed as a contraindication, it means the medicine is not permitted for use in that specific situation or by a person with that condition because the risks are considered to outweigh any potential benefit.

Q: Can Bornilene be taken if I have high blood pressure?

A: The official regulatory documents list no contraindications or warnings specifically concerning the use of Bornilene in individuals with high blood pressure.

Q: How does Bornilene affect the liver?

A: Official regulatory documents state there are no explicit restrictions or warnings listed regarding the use of Bornilene in individuals with hepatic (liver) impairment. This means the condition is not listed as a contraindication.

Q: Are there any known allergic reactions to Bornilene?

A: The official documentation states the product is contraindicated in cases of known hypersensitivity (severe allergy) to the active substance (Xibornol) or any of its non-active ingredients. If an allergy is known, the product is contraindicated for use.

Q: What is the risk of dependence or withdrawal with Bornilene?

A: The regulatory documentation reports the absence of documented adverse effects and contains no warnings regarding potential dependence or withdrawal symptoms. This is consistent with its classification as a topical antiseptic.

Q: Why is it important to follow the specified frequency for Bornilene?

A: The dosing instructions specify that administration should occur at regular intervals throughout the day. This is intended to ensure that consistent localized antimicrobial activity is maintained on the mucosal surface of the mouth and throat.

Q: What is the difference between an adverse event and a side effect of Bornilene?

A: Official terminology distinguishes a side effect as a known, expected, or commonly studied occurrence from an adverse event, which is any unexpected or unfavorable occurrence reported after the product is marketed. Both terms relate to safety monitoring.

Q: Is Bornilene considered a first-line treatment for the condition it addresses?

A: The use of Bornilene is described in official documents as an adjuvant (supportive) agent for the antisepsis of the oral cavity and pharynx. This means it is intended to be used in support of, or alongside, other appropriate treatments or hygiene measures.

How should Bornilene be stored and disposed of?

Official Storage and Disposal Requirements

Bornilene (Xibornol 30 mg/mL suspension spray) must be stored and disposed of according to the conditions defined in its governmental regulatory labeling.

Storage Conditions

Item	Requirement (As Documented in Official Sources)
Temperature	Does not require any particular storage condition (stable at ambient room temperature).
Child Protection	Must be kept out of the sight and reach of children.
Container	Store in the original container.

Stability and Disposal

The medicine has an unopened shelf life of two years. Once the bottle is first opened, the product must be used within 3 months. Unused or expired Bornilene must not be thrown into wastewater or household waste and is required to be disposed of in accordance with local regulations for pharmaceutical waste.

Bornilene